Forest plot for rate of sputum conversion in the initial phase

Forest plot for rate of sputum conversion in the initial phase of treatment (2 months after start of treatment).statistically significant difference between 4-FDC and SD treatments in terms of sputum conversion in the final phase of treatment. For the analysis of default, one study,25 did not collect related data. As it was not possible to contact the authors, this study was excluded from the analysis. The fixed-effects model was chosen because heterogeneity was not identified (p = 0.0775). The null hypothesis was not rejected (p = 0.9092), suggesting that there was no statistical evidence that the default differed between treatment groups. A forest plot (Fig. 4) showed that the 95 CI range for the log OR contained zero (log OR: 0.05, 95 CI: -0.82 to 0.92), indicating that the OR between treatments was statistically equal to one. Therefore, meta-analysis results did not reveal a statistically significant difference between 4-FDC and SD treatments in terms of default. For the analysis of the number of patients with AEs, two studies,14,23 did not collect related data and were excluded from the analysis, despite reasonable attempts to contactTable 2 ?Adverse events (AEs) reported in the included studies.Study No. of patients in FDC/SD group 26/25 AEs (no. of patients) in FDC group Hyperuricemia (8), skin itching (4), skin rash (2), drug fever (1), abnormal liver function (3) AEs (no. of patients) in SD group Hyperuricemia (7), skin itching (7), skin rash (2), abnormal liver function (5), gastrointestinal disorders (5), AnlotinibMedChemExpress Anlotinib blurred vision (2), sensation of numbness (1) Gastrointestinal disorders (89), skin reaction (67), muscle-joints (73) Gastrointestinal disorders (23), skin reaction (3), muscle-joints (0), death (1) Skin disorders (30); asthenia, headache, fever (5); musculo-skeletal disorders (22); liver and Vesatolimod chemical information biliary disorders (21); others (8) Rheumatological (11); dermatological (15); hepatic (1); and gastrointestinal (11) disorders; others (4). Default Relapse TB drug-related death Not evaluated b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 8 (2 0 1 7) 198?Su,Not evaluated1/57FDCGravendeel et al.,198/Zaka et al.,194/Gastrointestinal disorders (81), skin reaction (83), muscle-joints (64) Gastrointestinal disorders (28), skin reaction (8), muscle-joints (3) Skin disorders (40); asthenia, headache, fever (29); musculo-skeletal disorders (20); hepatic and biliary disorders (14); others (19) Rheumatological (7); dermatological (16); hepatic (5); and gastrointestinal (6) disorders; others (3)1/198 FDC, 2/162 SDNot evaluatedNot evaluated53/197 FDC, 30/99 SD0/293 FDC and SD1 case in group C with suspected TB meningitisBartacek et al.,558/25/558 FDC, 15/564 SD6/344 FDC, 3/360 SD2/558 FDC cases of hepatitisLienhardt et al.,798/40/798 FDC, 39/787 SD23/591 FDC, 19/579 SD4/591 FDC, 4/579 SDb r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 8 (2 0 1 7) 198?Su (2002) Gravendeel (2003) Zaka (2009) Lienhardt (2011)?.04 [ ?.00 , 3.92 ] 0.01 [ ?.94 , 0.96 ]Zaka (2008) Bartacek (2009)0.90 [ 0.19 , 1.61 ] ?.14 [ ?.42 , 0.14 ] 0.17 [ ?.32 , 0.66 ]0.32 [ ?.75 , 1.38 ] 0.14 [ ?.36 , 0.63 ] Lienhardt (2011)FE Model0.14 [ ?.27 , 0.54 ] RE Model ?.00 0.00 Log Odds Ratio 4.00 ?.50 0.50 1.50 0.24 [ ?.32 , 0.79 ]Fig. 3 ?Forest plot for sputum conversion in the final phase of therapy.Log Odds RatioFig. 5 ?Forest plot for number of patients with adverse effects.the authors of these studies. The random-effects model was chosen because heteroge.Forest plot for rate of sputum conversion in the initial phase of treatment (2 months after start of treatment).statistically significant difference between 4-FDC and SD treatments in terms of sputum conversion in the final phase of treatment. For the analysis of default, one study,25 did not collect related data. As it was not possible to contact the authors, this study was excluded from the analysis. The fixed-effects model was chosen because heterogeneity was not identified (p = 0.0775). The null hypothesis was not rejected (p = 0.9092), suggesting that there was no statistical evidence that the default differed between treatment groups. A forest plot (Fig. 4) showed that the 95 CI range for the log OR contained zero (log OR: 0.05, 95 CI: -0.82 to 0.92), indicating that the OR between treatments was statistically equal to one. Therefore, meta-analysis results did not reveal a statistically significant difference between 4-FDC and SD treatments in terms of default. For the analysis of the number of patients with AEs, two studies,14,23 did not collect related data and were excluded from the analysis, despite reasonable attempts to contactTable 2 ?Adverse events (AEs) reported in the included studies.Study No. of patients in FDC/SD group 26/25 AEs (no. of patients) in FDC group Hyperuricemia (8), skin itching (4), skin rash (2), drug fever (1), abnormal liver function (3) AEs (no. of patients) in SD group Hyperuricemia (7), skin itching (7), skin rash (2), abnormal liver function (5), gastrointestinal disorders (5), blurred vision (2), sensation of numbness (1) Gastrointestinal disorders (89), skin reaction (67), muscle-joints (73) Gastrointestinal disorders (23), skin reaction (3), muscle-joints (0), death (1) Skin disorders (30); asthenia, headache, fever (5); musculo-skeletal disorders (22); liver and biliary disorders (21); others (8) Rheumatological (11); dermatological (15); hepatic (1); and gastrointestinal (11) disorders; others (4). Default Relapse TB drug-related death Not evaluated b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 8 (2 0 1 7) 198?Su,Not evaluated1/57FDCGravendeel et al.,198/Zaka et al.,194/Gastrointestinal disorders (81), skin reaction (83), muscle-joints (64) Gastrointestinal disorders (28), skin reaction (8), muscle-joints (3) Skin disorders (40); asthenia, headache, fever (29); musculo-skeletal disorders (20); hepatic and biliary disorders (14); others (19) Rheumatological (7); dermatological (16); hepatic (5); and gastrointestinal (6) disorders; others (3)1/198 FDC, 2/162 SDNot evaluatedNot evaluated53/197 FDC, 30/99 SD0/293 FDC and SD1 case in group C with suspected TB meningitisBartacek et al.,558/25/558 FDC, 15/564 SD6/344 FDC, 3/360 SD2/558 FDC cases of hepatitisLienhardt et al.,798/40/798 FDC, 39/787 SD23/591 FDC, 19/579 SD4/591 FDC, 4/579 SDb r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 8 (2 0 1 7) 198?Su (2002) Gravendeel (2003) Zaka (2009) Lienhardt (2011)?.04 [ ?.00 , 3.92 ] 0.01 [ ?.94 , 0.96 ]Zaka (2008) Bartacek (2009)0.90 [ 0.19 , 1.61 ] ?.14 [ ?.42 , 0.14 ] 0.17 [ ?.32 , 0.66 ]0.32 [ ?.75 , 1.38 ] 0.14 [ ?.36 , 0.63 ] Lienhardt (2011)FE Model0.14 [ ?.27 , 0.54 ] RE Model ?.00 0.00 Log Odds Ratio 4.00 ?.50 0.50 1.50 0.24 [ ?.32 , 0.79 ]Fig. 3 ?Forest plot for sputum conversion in the final phase of therapy.Log Odds RatioFig. 5 ?Forest plot for number of patients with adverse effects.the authors of these studies. The random-effects model was chosen because heteroge.